Differential gene expression of BCL-2, ZEB2-AS1 and BALR-2 in prostate cancer and benign prostatic hyperplasia
Standard
Differential gene expression of BCL-2, ZEB2-AS1 and BALR-2 in prostate cancer and benign prostatic hyperplasia. / Ahani, Maryam; Ghaderian, Sayyed Mohammad Hossein; Mehr Azma, Mitra; Kamali, Koosha; Naghavi Gargari, Bahar; Bahramali, Golnaz; Akbarzadeh, Reza.
In: ANDROLOGIA, Vol. 54, No. 3, e14344, 04.2022.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Differential gene expression of BCL-2, ZEB2-AS1 and BALR-2 in prostate cancer and benign prostatic hyperplasia
AU - Ahani, Maryam
AU - Ghaderian, Sayyed Mohammad Hossein
AU - Mehr Azma, Mitra
AU - Kamali, Koosha
AU - Naghavi Gargari, Bahar
AU - Bahramali, Golnaz
AU - Akbarzadeh, Reza
N1 - © 2021 Wiley-VCH GmbH.
PY - 2022/4
Y1 - 2022/4
N2 - Prostate cancer (PCa) and benign prostate hyperplasia (BPH) are highly prevalent heterogeneous disorders among men. Whereas PCa and BPH underline common pathological features, apoptotic-related genes might be differentially expressed in these diseases. This study was aimed at testing BCL-2 as well as BALR-2 and ZEB2-AS1 apoptosis-related long non-coding RNA (lncRNA) in patients with PCa and BPH. The expression levels of the BCL-2 gene and ZEB2-AS1 lncRNA were upregulated in tumoural tissues in comparison to adjacent non-cancerous tissues (ANCTs) and BPH tissues. In contrast, the expression level of BALR-2 lncRNA was significantly higher in BPH compared with tumoural tissues. Furthermore, while no association was noticed between the relative expression of ZEB2-AS1 and the tumour grade, the relative expression of BCL-2 and BALR-2 is strongly associated with a higher grade of the tumour in PCa samples compared with the ANCTs. The receiver operating characteristic (ROC) curve analysis indicated the highest specificity and diagnostic value in distinguishing PCa and ANCTs as well as PCa and BPH, respectively. In conclusion, altered expression of BCL-2 and BALR-2 was observed to be associated with tumoural progression and could be used as potential candidates for distinguishing PCa tissues from ANCTs or BPH samples.
AB - Prostate cancer (PCa) and benign prostate hyperplasia (BPH) are highly prevalent heterogeneous disorders among men. Whereas PCa and BPH underline common pathological features, apoptotic-related genes might be differentially expressed in these diseases. This study was aimed at testing BCL-2 as well as BALR-2 and ZEB2-AS1 apoptosis-related long non-coding RNA (lncRNA) in patients with PCa and BPH. The expression levels of the BCL-2 gene and ZEB2-AS1 lncRNA were upregulated in tumoural tissues in comparison to adjacent non-cancerous tissues (ANCTs) and BPH tissues. In contrast, the expression level of BALR-2 lncRNA was significantly higher in BPH compared with tumoural tissues. Furthermore, while no association was noticed between the relative expression of ZEB2-AS1 and the tumour grade, the relative expression of BCL-2 and BALR-2 is strongly associated with a higher grade of the tumour in PCa samples compared with the ANCTs. The receiver operating characteristic (ROC) curve analysis indicated the highest specificity and diagnostic value in distinguishing PCa and ANCTs as well as PCa and BPH, respectively. In conclusion, altered expression of BCL-2 and BALR-2 was observed to be associated with tumoural progression and could be used as potential candidates for distinguishing PCa tissues from ANCTs or BPH samples.
KW - Gene Expression
KW - Humans
KW - Male
KW - Prostatic Hyperplasia/pathology
KW - Prostatic Neoplasms/pathology
KW - Proto-Oncogene Proteins c-bcl-2/genetics
KW - RNA, Long Noncoding
KW - Zinc Finger E-box Binding Homeobox 2/genetics
U2 - 10.1111/and.14344
DO - 10.1111/and.14344
M3 - SCORING: Journal article
C2 - 34866225
VL - 54
JO - ANDROLOGIA
JF - ANDROLOGIA
SN - 0303-4569
IS - 3
M1 - e14344
ER -
